Crinetics Pharmaceuticals CRNX Business Segments — Expenses Related To Atumelnant
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:ExpensesRelatedToAtumelnant.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — expenses related to atumelnant.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — expenses related to atumelnant?
- Crinetics Pharmaceuticals (CRNX) reported business segments — expenses related to atumelnant of $20.27M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — expenses related to atumelnant changed year-over-year?
- Crinetics Pharmaceuticals's business segments — expenses related to atumelnant increased by 161.5% year-over-year, from $7.75M to $20.27M.
- What does business segments — expenses related to atumelnant mean?
- This metric measures the total investment directed toward the research and development of the Atumelnant program. It reflects the financial resources dedicated to advancing this specific candidate through the clinical pipeline. High or increasing levels indicate active development efforts and the prioritization of this asset within the company's R&D strategy.